Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032

Blocking oncogenic signaling induced by the BRAFV600E mutation is a promising approach for melanoma treatment. We tested the anti-tumor effects of a specific inhibitor of Raf protein kinases, PLX4032/RG7204, in melanoma cell lines. PLX4032 decreased signaling through the MAPK pathway only in cell lines with the BRAFV600E mutation. Seven out of 10 BRAFV600E mutant cell lines displayed sensitivity based on cell viability assays and three were resistant at concentrations up to 10 μM. Among the sensitive cell lines, four were highly sensitive with IC50 values below 1 μM, and three were moderately sensitive with IC50 values between 1 and 10 μM. There was evidence of MAPK pathway inhibition and cell cycle arrest in both sensitive and resistant cell lines. Genomic analysis by sequencing, genotyping of close to 400 oncogeninc mutations by mass spectrometry, and SNP arrays demonstrated no major differences in BRAF locus amplification or in other oncogenic events between sensitive and resistant cell lines. However, metabolic tracer uptake studies demonstrated that sensitive cell lines had a more profound inhibition of FDG uptake upon exposure to PLX4032 than resistant cell lines. In conclusion, BRAFV600E mutant melanoma cell lines displayed a range of sensitivities to PLX4032 and metabolic imaging using PET probes can be used to assess sensitivity.

[1]  L. Fecher,et al.  Toward a molecular classification of melanoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  L. Chin,et al.  Oncogenic B-RAF negatively regulates the tumor suppressor LKB1 to promote melanoma cell proliferation. , 2009, Molecular cell.

[3]  K. Hemminki,et al.  Activating BRAF and N-Ras mutations in sporadic primary melanomas: an inverse association with allelic loss on chromosome 9 , 2003, Oncogene.

[4]  Chunrong Yu,et al.  BRAF V600E disrupts AZD6244-induced abrogation of negative feedback pathways between extracellular signal-regulated kinase and Raf proteins. , 2008, Cancer research.

[5]  Ming Zhou,et al.  Regulation of Raf-1 by direct feedback phosphorylation. , 2005, Molecular cell.

[6]  S. Gabriel,et al.  High-throughput oncogene mutation profiling in human cancer , 2007, Nature Genetics.

[7]  Carlo Gambacorti-Passerini,et al.  BRAF Silencing by Short Hairpin RNA or Chemical Blockade by PLX4032 Leads to Different Responses in Melanoma and Thyroid Carcinoma Cells , 2008, Molecular Cancer Research.

[8]  Ultan McDermott,et al.  Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma. , 2008, Cancer research.

[9]  C. Sander,et al.  V600EBRAF is associated with disabled feedback inhibition of RAF–MEK signaling and elevated transcriptional output of the pathway , 2009, Proceedings of the National Academy of Sciences.

[10]  A. Nicholson,et al.  Mutations of the BRAF gene in human cancer , 2002, Nature.

[11]  Kam Y. J. Zhang,et al.  Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity , 2008, Proceedings of the National Academy of Sciences.

[12]  M. Cascante,et al.  Fermented Wheat Germ Extract Inhibits Glycolysis/Pentose Cycle Enzymes and Induces Apoptosis through Poly(ADP-ribose) Polymerase Activation in Jurkat T-cell Leukemia Tumor Cells* , 2002, The Journal of Biological Chemistry.

[13]  Chao Zhang,et al.  RAF inhibitors transactivate RAF dimers and ERK signaling in cells with wild-type BRAF , 2010, Nature.

[14]  J. Reis-Filho,et al.  Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF , 2010, Cell.

[15]  F. Haluska,et al.  Genetic Alterations in Signaling Pathways in Melanoma , 2006, Clinical Cancer Research.

[16]  A. Aplin,et al.  Mutant B-RAF mediates resistance to anoikis via Bad and Bim , 2008, Oncogene.

[17]  J. Fridlyand,et al.  Distinct sets of genetic alterations in melanoma. , 2005, The New England journal of medicine.

[18]  Michael E. Phelps,et al.  Molecular imaging of lymphoid organs and immune activation using positron emission tomography with a new 18F-labeled 2′-deoxycytidine analog , 2008, Nature Medicine.

[19]  K. Flaherty,et al.  The MAPK pathway in melanoma , 2008, Current opinion in oncology.

[20]  K. Flaherty,et al.  Phase I study of PLX4032: Proof of concept for V600E BRAF mutation as a therapeutic target in human cancer. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  D. Barford,et al.  Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF , 2004, Cell.

[22]  Joseph T. Glessner,et al.  PennCNV: an integrated hidden Markov model designed for high-resolution copy number variation detection in whole-genome SNP genotyping data. , 2007, Genome research.

[23]  R. Marais,et al.  Melanoma biology and new targeted therapy , 2007, Nature.

[24]  Paul S Mischel,et al.  The AMPK agonist AICAR inhibits the growth of EGFRvIII-expressing glioblastomas by inhibiting lipogenesis , 2009, Proceedings of the National Academy of Sciences.

[25]  M. Phelps,et al.  Quantitative PET reporter gene imaging of CD8+ T cells specific for a melanoma-expressed self-antigen , 2008, International immunology.

[26]  K. Flaherty,et al.  Genetic subgrouping of melanoma reveals new opportunities for targeted therapy. , 2009, Cancer research.